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The chemotherapeutic drug methotrexate inhibits the enzyme dihydrofolate reductase 1 , which generates tetrahydrofolate, an essential cofactor in nucleotide synthesis 2 . Depletion of tetrahydrofolate causes cell death by suppressing DNA and RNA production 3 . Although methotrexate is widely used as an anticancer agent and is the subject of over a thousand ongoing clinical trials 4 , its high toxicity often leads to the premature termination of its use, which reduces its potential efficacy 5 . To identify genes that modulate the response of cancer cells to methotrexate, we performed a CRISPR-Cas9-based screen 6, 7 . This screen yielded FTCD, which encodes an enzyme-formimidoyltransferase cyclodeaminasethat is required for the catabolism of the amino acid histidine 8 , a process that has not previously been linked to methotrexate sensitivity. In cultured cancer cells, depletion of several genes in the histidine degradation pathway markedly decreased sensitivity to methotrexate. Mechanistically, histidine catabolism drains the cellular pool of tetrahydrofolate, which is particularly detrimental to methotrexate-treated cells. Moreover, expression of the rate-limiting enzyme in histidine catabolism is associated with methotrexate sensitivity in cancer cell lines and with survival rate in patients. In vivo dietary supplementation of histidine increased flux through the histidine degradation pathway and enhanced the sensitivity of leukaemia xenografts to methotrexate. The histidine degradation pathway markedly influences the sensitivity of cancer cells to methotrexate and may be exploited to improve methotrexate efficacy through a simple dietary intervention.
To identify genes that contribute to the response of cancer cells to methotrexate, we performed a genome-wide, positive-selection CRISPR-Cas9-based screen 6, 7 in the erythroleukaemia cell line HEL. We selected this cell line because of its high sensitivity to methotrexate in a competitive growth assay of 42 haematopoietic cell lines in the presence of methotrexate ( Fig. 1a, Extended Data Fig. 1a -c). 1 Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Department of Biology, Cambridge, MA, USA. 2 The cell lines were pooled together and treated with 0, 0.1, 0.5 and 5 μM methotrexate for 6 days. Genomic barcodes were sequenced to determine the relative representation of each line in the mixed culture at the various methotrexate concentrations. The erythroleukaemia HEL cell line was identified as a sensitive cell line suitable for a genome-wide, positive-selection CRISPR-Cas9-based screen. b, The two top hits in the CRISPR-Cas9-based screen 6, 7 were SLC19A1 and FTCD. Genes were ranked by the difference between their CRISPR score 10 in the methotrexate-treated and the vehicle-treated samples. c-e, Targeting FTCD by CRISPR-Cas9 in HEL cells decreased their sensitivity to methotrexate. c, Fold change in the EC 90 of methotrexate in HEL cells that were treated with methotrexate for 5 days and stably expressing the indicated constructs. EC 90 values for methotrexate are relative to wild-type (WT) cells (n = 3, except for SLC19A1 for which n = 2, biological replicates). d, HEL cells stably expressing the indicated constructs were counted daily to assess their survival after treatment with 5 μM methotrexate (n = 3, biological replicates). e, Differential interference contrast micrographs of HEL cells stably expressing the indicated constructs and treated with 5 μM methotrexate for 3 days. Scale bar, 100 μm. A representative experiment is presented (n = 3, biological replicates). f, CRISPR-Cas9-depletion of FTCD decreased the sensitivity of additional cell lines (Ramos and LAMA84) to methotrexate. Shown are fold changes in the EC 90 values of methotrexate and the control drug, doxorubicin, compared to wild-type cells (n = 3, biological replicates, ordinary one-way ANOVA, comparing sgFTCD to each of the other samples. For doxorubicin all P values were not significant). In c, d, f, error bars indicate s.e.m. Abbreviations: mFTCD, cells stably expressing mouse Ftcd cDNA that is not targeted by the sgRNA used in this experiment; sgAAVS, cells stably expressing an sgRNA targeting the non-coding AAVS locus 6, 7 ; sgFTCD, cells stably expressing an sgRNA targeting FTCD; sgSLC19A1, cells stably expressing an sgRNA targeting SLC19A1.
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We focused our efforts on haematopoietic cell lines because methotrexate is most frequently used to treat haematopoietic malignancies 9 . The two highest-scoring 10 genes in the screen were SLC19A1 and FTCD (Fig. 1b , Extended Data Fig. 1d, e ). SLC19A1 is a reduced folate transporter that imports methotrexate into cells, and its depletion reduces methotrexate sensitivity in cultured cells 11 and in patient tumours 12, 13 .
FTCD is an enzyme involved in histidine catabolism and has not previously been associated with methotrexate sensitivity. Depletion of FTCD using two distinct single-guide RNAs (sgRNAs) increased the EC 90 (90% of maximal effective concentration) of methotrexate by more than tenfold relative to controls ( Fig. 1c-e ). Importantly, expression of the murine Ftcd cDNA, which is resistant to sgRNA-mediated targeting, re-sensitized FTCD-depleted cells to methotrexate, validating the results of our screen ( Fig. 1c-f ). RNA interference (RNAi)mediated knockdown of FTCD also increased the EC 90 of methotrexate (Extended Data Fig. 1f , g), which suggests that even subtle reductions in FTCD expression are sufficient to alter methotrexate sensitivity. CRISPR-Cas9-mediated depletion of FTCD also decreased the sensitivity of Ramos (Burkitt's lymphoma) and LAMA84 (chronic myeloid leukaemia) cells to methotrexate ( Fig. 1f , Extended Data Fig. 1h ), which demonstrates that our findings are generalizable to cell lines derived from additional haematopoietic malignancies.
FTCD catalyses two reactions in the histidine degradation pathway 14 (Fig. 2a , Extended Data Fig. 2a ). The formimidoyltransferase domain metabolizes tetrahydrofolate (THF) and the histidinebreakdown product formiminoglutamic acid (FIGLU) to produce glutamate and 5-formimino THF. The cyclodeaminase domain further metabolizes 5-formimino THF to 5,10-methenyl THF 14 . We profiled FTCD-relevant metabolites in FTCD-depleted HEL and Ramos cells using liquid chromatography coupled with mass spectrometry (LC-MS). Depletion of FTCD increased the levels of histidine ( Fig. 2b , top, Extended Data Fig. 2b ), and decreased the levels of 5,10-methenyl THF ( Fig. 2b , middle, Extended Data Fig. 2b ) and the downstream metabolite 5-formyl THF (Fig. 2b , bottom, Extended Data Fig. 2b ). The modest decline in 5,10-methenyl THF is probably due to an additional pool of this metabolite, synthesized by the enzyme methylenetetrahydrofolate dehydrogenase 1 (MTHFD1). This pool of 5,10-methenyl THF is directly channelled to 10-formyl THF by MTHFD1 and is unlikely to serve as a substrate for the build-up of 5-formyl THF 15 . These data indicate that depletion of FTCD decreases flux through the histidine degradation pathway.
Methotrexate treatment causes a decrease in the cellular pool of THF, which inhibits nucleotide synthesis and is considered to be the main cause of cell death by the treatment 3 . The use of THF by FTCD results in the synthesis of 5-formyl THF, a folate entity that has no described role as an enzyme cofactor and is considered to be a storage form of folate 16 (Fig. 2c , Extended Data Fig. 2d ). We proposed that the consumption of THF by FTCD for the synthesis of 5-formyl THF would be particularly harmful to cells in which the THF pool is already limiting, such as in methotrexate-treated cells. Indeed, depletion of the FTCD gene resulted in significantly higher levels of THF in methotrexatetreated cells (Fig. 2d 
We observed significantly higher levels of inosine monophosphate (IMP) and thymidine triphosphate (TTP) after methotrexate treatment in FTCD-depleted cells compared to control cells ( Fig. 2d middle and bottom), which suggests that the increased THF pool size in these cells contributes to nucleotide biosynthesis. To examine the ability of methotrexate-treated, FTCD-depleted cells to synthesize nucleotides, we used uniformly labelled (U-) [ 13 C]serine to label newly synthesized nucleotides in cells treated with methotrexate. Loss of FTCD significantly increased the labelling of IMP and TTP in methotrexate-treated cells ( Fig. 2e ), without changing the overall labelling efficiency (Extended Data Fig. 2e , f) or the cellular pools of glycine and serine (Extended Data Fig. 3a, b ). These results suggest that FTCD depletion enables the survival of methotrexate-treated cells by sparing cellular THF pools, and thus enabling de novo nucleotide synthesis to continue.
To determine the contribution of other components of the histidine degradation pathway ( Fig. 2a ) to methotrexate sensitivity, we genetically targeted histidine ammonia lyase (HAL) and amidohydrolase domain containing 1 (AMDHD1), two enzymes of the histidine degradation pathway that function upstream of FTCD [17] [18] [19] . Similar to our findings with FTCD, CRISPR-Cas9-mediated depletion of these enzymes decreased the sensitivity of cells to methotrexate ( Fig. 3a , Extended Data Fig. 4a ). As in FTCD-depleted cells, methotrexate-treated, HALdepleted cells had significantly higher levels of THF (Fig. 3b, top) , and higher rates of nucleotide synthesis as monitored by [U-13 C]serine tracing in comparison to control cells (Fig. 3b , middle and bottom). Notably, whereas control cell lines show increased total serine and [U-13 C]serine levels upon methotrexate treatment, HAL-depleted HEL cells show total and [U-13 C]serine levels that are similar to vehicle-treated cells (Extended Data Fig. 4d , f). The increased serine levels in methotrexate-treated control cells are probably the result of reduced serine usage owing to limiting cellular levels of THF. Glycine labelling appears to be the same in all samples (Extended Data Fig. 4c, e ). These data suggest that, as with the depletion of FTCD, the depletion of HAL results in a higher availability of reduced folate and thus greater nucleotide synthesis rates in cells treated with methotrexate.
We found that the expression of HAL-which encodes the ratelimiting enzyme in the histidine degradation pathway 20 -but not of FTCD or AMDHD1 was significantly higher ( Fig. 3c , Extended Data Fig. 4b ) in haematopoietic cell lines that we identified as being highly sensitive to methotrexate ( Fig. 1a , Extended Data Fig. 1a -c). To follow up on this finding, we analysed RNA-seq data from 1,010 cell lines 21 to identify those with the highest and lowest expression of HAL (Fig. 3d) , and found that cell lines with high HAL expression were more sensitive to methotrexate than those with low expression ( Fig. 3e ). Depletion of HAL in two high HAL-expressing lines (EOL-1 and NCIH1666) substantially decreased their methotrexate sensitivity ( Fig. 3f , Extended Data Fig. 5a ), revealing a functional role for HAL in the response of these cells to the drug. Thus, cells with endogenously low or 13 C]serine labelling (n = 3, biological replicates; for THF, one-way ANOVA; for AMP and TTP, two-way ANOVA for the unlabelled fraction). c, HAL expression is significantly higher in cells that are more sensitive to methotrexate. The response to methotrexate was determined in a pooled fashion using genomically barcoded cell lines ( Fig. 1a ). HAL expression was measured by qPCR (n = 4 for resistant cell lines and n = 6 for sensitive cell lines, biologically independent samples, two-tailed Kolmogorov-Smirnov test). d, e, Differences in HAL expression are associated with methotrexate sensitivity in cancer cell lines. d, Cell lines were ranked by HAL expression according to RNA-seq data 21 Letter reSeArCH exogenously lowered HAL expression are both less sensitive to methotrexate than control cells. Methotrexate is used as the standard of care in the treatment of the most common paediatric malignancy, acute lymphoblastic leukaemia (ALL) 22 , with relatively high success rates that unfortunately are accompanied by severe toxicity 5 . At present, treatment-outcome prediction markers are lacking 23 , leading physicians to prescribe methotrexate regimens based on clinical parameters instead of personalized pharmacogenetic factors. Notably, we found that young patients with ALL that showed high HAL expression in the ALL cells have significantly higher survival rates, compared to patients in the same study 24 with low HAL expression ( Fig. 3g ). Expression levels of SLC19A1, which encodes the transporter for methotrexate, as well as the genes (AMDHD1 and FTCD) encoding histidine degradation pathway enzymes showed no significant association with patient survival (Extended Data Fig. 5b-d) . These data warrant further investigation of the expression level of HAL as a prediction factor for treatment success rate in patients with ALL that are treated with methotrexate.
The association between expression levels of the rate-limiting enzyme in the histidine degradation pathway and methotrexate sensitivity in cancer cell lines and patients raised the possibility that increasing flux through this pathway could enhance the cytotoxic effects of methotrexate. We proposed that in vivo histidine supplementation would increase histidine degradation and consumption of THF by FTCD, which might enhance the toxic effects of methotrexate on tumour cells. To assess the response of cancer cells to methotrexate in the presence of above-normal levels of histidine, we generated tumours by injecting HEL or SEM cells subcutaneously into NOD-SCID mice and treated the tumour-bearing mice with vehicle, histidine, methotrexate or a combination of histidine and methotrexate ( Fig. 4a ). To reliably assess the contribution of histidine supplementation, we intentionally used a mild regimen of methotrexate consisting of doses lower than those normally used in mice 25 .
As expected, tumours from mice treated with this reduced dosing of methotrexate did not have a significant decrease in size ( Fig. 4b, c , Extended Data Fig. 6a, b ). However, tumours from mice given both methotrexate and histidine showed a marked decrease in tumour size that was significantly greater than in any of the other treatment cohorts (Fig. 4b, c ). Additionally, tumours from mice treated with methotrexate and histidine supplementation appeared histologically worse and contained large necrotic areas and what morphologically appeared to be necrotic or apoptotic cells ( Fig. 4d-f , Extended Data Figs. 6c, d, 7a ). Organs known to be adversely affected by methotrexate showed no further toxicity in mice treated with the combined therapy compared to mice treated with methotrexate alone (Extended Data Figs. 7b, 9a), and no difference was observed in the weight loss of the mice treated with methotrexate alone compared to methotrexate treatment supplemented with histidine (Extended Data Fig. 9b ). No enhanced toxicity was observed in mice treated with the combined therapy compared to methotrexate alone even when the mice were treated for 15 days (Extended Data Figs. 10, 11 ).
According to our hypothesis, histidine supplementation should increase the flux through the histidine degradation pathway and cause . e, f, The combination of methotrexate and histidine supplementation was the only treatment that resulted in significant necrosis in tumours. Necrotic areas as detected by haematoxylin and eosin staining (d, top three rows, right column) were measured in the different groups (non-parametric oneway ANOVA, Kruskal-Wallis test, Dunn's post hoc test). g, THF levels decreased after methotrexate treatment and decreased even further when methotrexate was combined with histidine supplementation. Methotrexate levels were not different in tumours from mice treated with methotrexate alone or in combination with histidine supplementation. Nucleotide abundance was significantly lower in tumours from mice treated with methotrexate and histidine supplementation compared to tumours from vehicle-treated mice (non-parametric one-way ANOVA, Kruskal-Wallis test, Dunn's post hoc test. Methotrexate, two tailed t-test). b, d, e, vehicle (n = 5), histidine (n = 4), methotrexate (n = 6), methotrexate + histidine (n = 6). c, f, (n = 6), (n = 7), (n = 7), (n = 7) for the same groups. g, (n = 5), (n = 4), (n = 5), (n = 6), for the same groups. Centre bars indicate mean, error bars indicate s.e.m.
Letter reSeArCH increased consumption of THF, a limiting metabolite in methotrexate-treated tumours. Notably, THF levels were significantly lower in tumours from mice treated with the combined therapy compared to methotrexate alone, which suggests lower THF availability in these tumours, although methotrexate levels were not different ( Fig. 4g , Extended Data Fig. 8 ). Both methotrexate and folate levels were very similar in the plasma of mice treated with methotrexate alone or in combination with histidine supplementation (Extended Data Fig. 9e, f) . Metabolites of the histidine degradation pathway were increased in HEL-cell-derived tumours in mice treated with histidine supplementation (Extended Data Fig. 9c, d) .
Lower availability of THF should compromise the capacity of cells to synthesize nucleotides, which are essential for cell proliferation and viability. Indeed, the levels of AMP, GMP and TMP in tumours from mice treated with both methotrexate and histidine were significantly lower than those found in tumours from vehicle-treated mice (Fig. 4g , Extended Data Fig. 8 ). Collectively, our data indicate that histidine supplementation can increase the efficacy of methotrexate in mice in vivo by enhancing the depletion of THF within tumour cells.
Taken together, our results provide evidence for a role of the histidine degradation pathway in the cellular response to the widely used chemotherapy agent methotrexate. Endogenous expression levels of HAL, which encodes the rate-limiting enzyme of the pathway, are associated with the sensitivity of cancer cell lines to methotrexate, and the overall survival of patients with ALL who are treated with methotrexate. These findings suggest that HAL expression might serve as a clinical predictor for better responders to methotrexate treatment among patients with ALL, and may be informative for decisions regarding therapy strategies. Furthermore, both genetic perturbation and dietary enhancement of the pathway changed the sensitivity of haematopoietic cancer cells to the chemotherapy. As standard protocols for administering methotrexate are often accompanied by severe toxicity 5 , we suggest that dietary supplementation with histidine could represent a relatively low-risk intervention that might enable reduced dosing of this toxic agent and therefore a greater clinical benefit.
Online content
Any Methods, including any statements of data availability and Nature Research reporting summaries, along with any additional references and Source Data files, are available in the online version of the paper at https://doi.org/10.1038/s41586-018-0316-7. Construction of unique barcoded plasmids. The oligonucleotides BC-top and BC-bottom were annealed and phosphorylated (T4 PNK, NEB) to generate a linear DNA fragment containing a 5′-AgeI overhang, a 3′-EcoRI overhang, and a degenerate NNNNNNN 7-mer (N is A, T, G, C). The annealed product was cloned into pLKO to generate a collection of pLKO-BC plasmids containing unique 7-mer barcodes that were subsequently determined by Sanger sequencing, as similarly described elsewhere 29 .
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BC-top: CCGGTTTTTAGCATCGCCNNNNNNNCTCGCGGCCGCAGGTCCATG BC-bottom: AATTCATGGACCTGCGGCCGCGAGNNNNNNNGGCGATGCTAAAAA Virus production. HEK-293T cells were co-transfected with a pLKO-BC plasmid, the VSV-G envelope plasmid and the ΔVPR lentiviral packaging plasmid using XTremeGene 9 Transfection Reagent (Roche). Culture medium was exchanged 16 h after transfection with the same medium instead supplemented with 20% inactivated fetal bovine serum (IFS). The virus-containing supernatant was collected 48 h after transfection and passed through a 0.45-μm filter to eliminate cells. Transduction of cell lines. Cells were pelleted, then seeded at a density of 300,000 cells per ml in 6-well plates in 2 ml of RPMI containing 8 μg ml −1 polybrene (EMD Millipore), and then transduced with lentivirus by centrifugation at 1,200g for 90 min at 37 °C. After a 24-h incubation, cells were pelleted to remove virus and then re-seeded into fresh culture medium containing puromycin, and selected for 72 h. Competitive survival of barcoded cell lines. Forty-two haematopoietic cancer cell lines that each carried a stably incorporated specific genomic barcode were pooled together and treated for 6 days with methotrexate (0, 0.1, 0.5 and 5 μM). Genomic DNA (gDNA) samples were collected at days 2, 4 and 6 and barcode abundances were determined by high-throughput sequencing (Illumina MiSeq). Positive-selection CRISPR-Cas9-based screen. Before the screen, the EC 90 of methotrexate in HEL cells was determined in culture conditions similar to the screen. Detailed protocols for the CRISPR-Cas9-based screen are described elsewhere [30] [31] [32] . In short, the sgRNA library 7 was transformed and propagated for virus production as described above, followed by HEL transduction at an efficiency of 60% to avoid more than one sgRNA in each cell. After selection of transduced cells by puromycin, cells were divided into two replicates each of DMSO-and methotrexate-treated groups and were cultured for 14 days. Cells (100 × 10 6 ) were collected for genomic DNA purification and sgRNA library deconvolution by HiSeq deep sequencing. Sequencing reads were aligned to the sgRNA library and the abundance of each sgRNA was calculated 10 . The counts from all replicates of the initial cell populations were combined to generate the initial reference dataset. The counts from each sample were normalized for sequencing depth. sgRNAs with fewer than 40 reads in the initial reference dataset were omitted from downstream analyses. The log 2 fold change in abundance of each sgRNA between the final and initial reference populations was calculated and used to define a CRISPR score for each gene 10 . The CRISPR score is the average log 2 fold change in abundance of all sgRNAs targeting a given gene. Genes targeted by fewer than four distinct sgRNAs in the initial reference dataset were omitted from downstream analyses. Gene targeting using single sgRNAs. To generate HEL, Ramos, LAMA84, EOL-1 and NCIH1666 cells stably expressing the indicated sgRNAs, the following oligonucleotides were cloned into the pLentiCRISPR V1 viral vector. Oligonucleotides used for sgRNA cloning. sgAAVS: caccgTCCCCTCCACCCCA-CAGTG (sense), aaacCACTGTGGGGTGGAGGGGAc (antisense). sgFTCD_1: caccgGCA GGTTGAGCGCGATGCGG (sense), aaacCCGCATCGCGCT-CAACCTGCc (antisense). sgFTCD_2: caccgGGAGCCATCACACAGACCCC (sense), aaacGGG GTCTGTGTGATGGCTCCc (antisense). sgSLC19A1: caccgTG-CGCGGGTCTA CAACGGCG (sense), aaacCGCCGTTGTAGACCCGCGCAc (antisense). sgHAL: caccgGCAGGCAGCTCACTGAGGGA (sense), aaacTCCCT-CAGTGA GCTGCCTGCc (antisense). sgAMDHD1: accgATGGAAATTCAC-CAGGCCGG (sense), aaacCCGGCCTGGTGAATTTCCATc (antisense).
To generate lentivirus, 3 × 10 6 HEK-293T cells were seeded in a 10-cm plate in DMEM supplemented with 10% IFS. After 24 h, the cells were transfected with the above sgRNA pLenti-encoding plasmids alongside the ΔVPR envelope and CMV VSV-G packaging plasmids using the XTremeGene 9 Transfection Reagent (Roche). Twelve hours after transfection, the medium was aspirated and replaced with 8 ml of fresh medium. Virus-containing supernatants were collected 48 h after the transfection and passed through a 0.45-μm filter to eliminate cells. The transduction of cells was performed as described above. Gene knockdowns using shRNAs. Lentiviral shRNAs were obtained from The RNAi Consortium 33 . Lentivirus production and viral transduction of HEL cells were performed as described above, followed by a three-day selection with puromycin. Knockdown was verified 48 h after completion of selection by qPCR. shRNA sequences. GFP, TGCCCGACAACCACTACCTGA. RFP, CGCGTGAT GAACTTCGAGGAC. LacZ, CCAACGTGACCTATCCCATTA. FTCD shRNA 1, CCGGGTAGCTTCCCGACTTAT. FTCD shRNA 2, CGAGAAG GAGAACCTCTTCAT. SLC19A1 shRNA 1, CGACGGTGTTCAGAATGTGAA. SLC19A1 shRNA 2, GATTGCATCTTCTCTGTCTAA. Methotrexate treatment of cell lines in culture. Unless otherwise indicated, 5 μM methotrexate (Sigma) was added to RPMI supplemented with 10% IFS for at least 3 days. Owing to their relatively low sensitivity to the drug, Ramos cells were treated with 20 μM methotrexate. Cell survival assays. Cells were seeded at a cell density of 50,000 cells per ml in 96-well plates. Three hours later, cells were treated with 7-10 concentrations of methotrexate or doxorubicin in triplicate. Cells were incubated for 5 days, after which an ATP-based, cell viability assay was performed (CellTiter Glo, Promega). Survival curves were calculated by best-fit analysis of the log of the drug concentration (in μM) to fold change of treated cells over vehicle-treated cells. All survival assays included technical triplicates per sample, per experiment. Cell counting. Cells were counted using a Coulter Counter (Beckman Z2). The percentage viability was calculated by a FACS-based (BD LSR flow cytometer) viability assay using 7-AAD staining (Thermo Fisher Scientific). Each experiment included technical triplicates per sample. Metabolite profiling by mass spectrometry. Sample preparation for polar metabolite detection. For cells in culture, two million cells were collected, washed once with 0.9% NaCl and resuspended in extraction buffer (80% methanol, 20% H 2 O plus isotopically labelled internal standards). Samples were then mixed by vortexing for 10 s and the debris was pelleted by a 10-min spin at 18,000g. The supernatant was then transferred to a new tube and dried using a liquid nitrogen dryer.
For tumours, the tumours were collected and immediately snap-frozen in liquid nitrogen. Tumours were thawed by homogenization (Kimble cordless handheld homogenizer) in extraction buffer, followed by the procedure described for cell culture samples. All metabolites measured in tumours were normalized to an average of four amino acids (phenylalanine, leucine, valine and tyrosine) as an internal loading control.
For plasma samples, blood was collected from the submandibular vein into anticoagulant tubes (Microvette, Sarstedt), and immediately placed on ice. Samples were spun for 6 min at 1,000g and supernatants were collected. From each sample, 10 μl was collected and used for further LC-MS analysis by extraction in 90 μl extraction buffer and sample preparation as described for cultured cells. Sample preparation for folate detection. The protocol for folate detection was similar to that previously described 34 , and adapted with a minor change: the extraction buffer used was 80% methanol, 20% 12.5 mM sodium ascorbate. All subsequent steps were as described 34 . In brief, samples were washed once (0.9% NaCl), then extracted in extraction buffer (80% methanol, 20% 12.5 mM sodium ascorbate, plus aminopterin as internal standard), mixed by vortexing for 10 s and debris was pelleted by a 10-min spin at 18,000 g. Supernatants were split for polar metabolite and folate detection and dried using a liquid nitrogen dryer manifold. Polar samples were resuspended in water to be run in the mass spectrometer. Folate samples were resuspended in reconstitution buffer (0.5% ascorbic acid, 1% K 2 HPO 4 and 0.5% 2-mercaptoethanol) containing rat serum (Sigma, R9759). The rat serum contains the enzymes required to strip the polyglutamate tail from the measured folate. Rat endogenous folate was removed from the rat serum by activated carbon treatment (Sigma, C9157). Polyglutamate tail removal was carried out for 2 h at 37 °C. After the polyglutamate tail removal, the pH was adjusted to 4 using formic acid and samples were loaded on Bond Elute-pH columns (Agilent, 14102062) for a pH-based clean-up. Columns were eluted with 300 μl elution buffer (50% methanol, 0.25% NH 4 OAc, 0.5% 2-mercaptoethanol), followed by drying the samples using a liquid nitrogen dryer manifold and resuspension in 50 μl water. Polar metabolite profiling by LC-MS. Dried polar samples were resuspended in 50 μl water and 2 μl was injected into a ZIC-pHILIC 150 × 2.1 mm (5 μm particle size) column (EMD Millipore). Analysis was conducted on a QExactive benchtop Orbitrap mass spectrometer equipped with an Ion Max source and a HESI II probe, which was coupled to a Dionex UltiMate 3,000 UPLC system (Thermo Fisher Scientific). External mass calibration was performed using the standard calibration mixture every 7 days. Chromatographic separation was achieved using the following conditions: buffer A was 20 mM ammonium carbonate, 0.1% ammonium hydroxide; buffer B was acetonitrile. The column oven and autosampler tray were Letter reSeArCH held at 25 °C and 4 °C, respectively. The chromatographic gradient was run at a flow rate of 0.150 ml min −1 as follows: 0-20 min: linear gradient from 80% to 20% B; 20-20.5 min: linear gradient from 20% to 80% B; 20.5-28 min: hold at 80% B. The mass spectrometer was operated in full-scan, polarity switching mode with the spray voltage set to 3.0 kV, the heated capillary held at 275 °C, and the HESI probe held at 350 °C. The sheath gas flow was set to 40 units, the auxiliary gas flow was set to 15 units, and the sweep gas flow was set to 1 unit. The data acquisition was performed over a range of 70-1,000 m/z, with the resolution set at 70,000, the automatic gain control target at 10e6, and the maximum injection time at 20 ms. Relative quantitation of polar metabolites was performed with XCalibur QuanBrowser 2.2 (Thermo Fisher Scientific) using a 5 p.p.m. mass tolerance and referencing an in-house library of chemical standards.
Histidine was normalized to isotopically labelled histidine as an internal standard; IMP, AMP and TTP levels were normalized to isotopically labelled glutamate as an internal standard. Detection of folate species by LC-MS. Detection of folate species was performed on the same instrumentation described above. In general, instrument settings remained the same unless specified. After removal of the polyglutamate tails from folate species 34 , samples were resuspended in 50 μl water and 15 μl was injected onto an Ascentis Express C18 HPLC column (2.7 μm × 15 cm × 2.1 mm; Sigma Aldrich). The column oven and autosampler tray were held at 30 °C and 4 °C, respectively. The following conditions were used to achieve chromatographic separation: buffer A was 0.1% formic acid; buffer B was acetonitrile with 0.1% formic acid. The chromatographic gradient was run at a flow rate of 0.250 ml min −1 as follows: 0-5 min: gradient was held at 5% B; 5-10 min: linear gradient of 5% to 36% B; 10.1-14.0 min: linear gradient from 36-95% B; 14.1-18.0 min: gradient was returned to 5% B. The mass spectrometer was operated in full-scan, positive ionization mode. Data acquisition was performed using three narrow-range scans: 438-450 m/z; 452-462 m/z; and 470-478 m/z, with the resolution set at 70,000, the automatic gain control target at 10e6, and the maximum injection time of 150 ms. Relative quantitation of folate species was performed with XCalibur QuanBrowser 2.2 (Thermo Fisher Scientific) using a 5 p.p.m. mass tolerance. Non-glutamated folate species were identified using chemical standards (see below), together with comparison of experimental MS2 spectra with in silico predicted spectra ( Supplementary Fig. 1 ) Mirror plots were created using R and structures were identified based on the known parental structure (HMDB, www.hmdb.ca), using a combination of ChemDraw (PerkinElmer), CFM:ID 35 (cfmid.wishartlab.com), METLIN (metlin.scripps.edu) and Sirius 36, 37 (version 3.5.1).
The standards for different forms of folate are as follows: aminopterin (Sigma, A3411); folate (Schircks Laboratories, 16.203); THF (Schircks Laboratories, 16.207), 5-formyl THF (Schircks Laboratories, 16.221); triglutamate 5-formyl THF (Schircks Laboratories, 16.283); 5,10-methenyl THF (Schircks Laboratories, 16.230); 5-methyl THF (Schircks Laboratories, 16.235). Levels of all folate forms, as well as methotrexate were normalized to aminopterin as an internal standard. Mass spectrometry reagents. Chloroform was purchased from Sigma-Aldrich and was HPLC grade (ethanol-stabilized). Acetonitrile was purchased from Merck Millipore and was LC-MS Hypergrade. All other solvents were purchased from Fisher and were Optima LC-MS grade. Folate standards were purchased from Schircks laboratories. A mix of 17 isotopically labelled amino acids (Cambridge Isotope Laboratories) was used as the internal standard. FIGLU standard was purchased from Dalton Research Molecules (DC-001551). Labelling with [U-13 C]serine. Cells (500,000) were seeded in RPMI containing 10% dialysed IFS and cultured for 24 h. For FTCD-null cells ( Fig. 2e) , HEL cells were treated with 5 μM methotrexate for 48 h, and Ramos cells were treated with 20 μM methotrexate for 72 h to decrease THF levels and nucleotide synthesis in wild-type cells. The medium was then replaced with [U-13 C]serine-containing medium by counting 1 × 10 6 cells that were washed once with PBS, and reseeded in RPMI containing 10% dialysed IFS that contained [U-13 C]serine and no unlabelled serine. Cells were incubated in [U-13 C]serine plus methotrexate for an additional 24 h followed by cell collection and LC-MS analysis. For HAL-null cells (Fig. 3b) , Ramos cells were treated with 20 μM methotrexate for 48 h before [U-13 C]serine labelling to decrease THF levels and nucleotide synthesis in wild-type cells. The medium was then replaced with [U-13 C]serine-containing medium by counting 1 × 10 6 cells that were washed once with PBS, and reseeded in RPMI containing 10% dialysed IFS that contained [U-13 C]serine and no unlabelled serine. Cells were incubated in [U-13 C]serine plus methotrexate for an additional 24 h followed by cell collection and LC-MS analysis. HEL cells were treated with 5 μM methotrexate for 24 h, in parallel with the [U-13 C]serine labelling. Vehicle-treated cells were treated with equivalent concentrations of DMSO for the same times. Natural abundances of labelled nucleotides were corrected as previously described 38, 39 . Quantitative PCR. Cell pellets were washed once with PBS before RNA purification using Trizol (ambion). The reverse transcriptase reaction was performed using 2 μg RNA from each sample (SuperScript III, Thermo Fisher Scientific). Quantitative PCR (qPCR) reactions were performed with SYBR green reagent (Roche) and according to the manufacturer's instructions. The QuantStudio 6 Flex (Applied Biosystems) qPCR instrument was used for all reactions. The reference genes used in each qPCR run were UBC and HPRT1. Primers used for qPCR. FTCD: forward primer: TGCGAGAAGGAGAACCTCTT, reverse primer: CTCGATGATCCGCTCCTTAG. HAL: forward primer: GGCTG AAGGTGGTCTGAACT, reverse primer: AGTCAACAGACGAGGGATGG. AMDHD1: forward primer: AGTCTCACACACACGGATCG, reverse primer: GCCT CCGAACTGGTAAATCA. SLC19A1: forward primer: GAGAGCTTCA TCACCCCCTA, reverse primer: GGCCAGGTAGGAGTACGACA. Mouse Ftcd: forward primer: AACCTGCTAAGCACCAAGGA, reverse primer: GGACC TTTTTCAGACGTCCA. mouse Hal: forward primer: GGTGGCCTT AGAGGACAATG, reverse primer: GCTCCCGGTATTTGCTGTAG. Mouse Amdhd1: forward primer: TCCACGAGTTTGCAATGAAG, reverse primer: CTCCACCGTGAAGTTGATCC. GFP: forward primer: ACAACGTCTA TATCATGGCCGA, Reverse primer: GAAGTTCACCTTGATGCCGTTC. UBC: Forward primer: ATTTGGGTCGCGGTTCTT, Reverse primer: TGCCTTGACATTCTCGATGGT. HPRT1: Forward primer: TGAC ACTGGCAAAACAATGCA, Reverse primer: GGTCCTTTTCACCAGCAAGCT. Mouse tumour xenografts. HEL and SEM cells were transduced with R-luciferase expressing vector (FUW-RLuc-T2A-PuroR), and selected with puromycin. Cells (2 × 10 6 ) were injected subcutaneously into 50 NOD-SCID mice (HEL) or 30 NOD-SCID mice (SEM). Three weeks after injection, tumour size was imaged using the IVIS Spectrum in vivo imaging system (PerkinElmer) after intraperitoneal injection of 50 μg per mouse of the water-soluble substrate Coelenterazine (Nanolight Technologies). A total of 24 mice (HEL) or 27 mice (SEM) with similar tumour sizes were divided into four experimental groups: vehicle-treated (saline), histidine supplementation (400 μl of histidine solution of 46 mg ml −1 , histidine maximum solubility at 25 °C), methotrexate-treated (50 mg kg −1 methotrexate, based on the weight measured at the day of first imaging), and histidine supplementation combined with methotrexate treatment. Mice were then injected daily for 5 days. All solutions were warmed to 37 °C before injection to reduce stress. After five days of treatment, tumour size was monitored, and tissues were collected for LC-MS and histology. The Committee for Animal Care at the Massachusetts Institute of Technology (MIT) approved all animal procedures carried out in this study. Mice were euthanized when tumours reached the size limit of 1 cm or if other symptoms indicative of low health status appeared. These included lethargy, drop in weight (10% over a day or 20% since the beginning of the experiment), reduced appetite, lack of movement, hunched back and hair loss.
We have complied with all relevant ethical regulations while conducting animal experiments. Sample size was determined as the minimal number of mice absolutely necessary for reliable, significant results (no less than 6 and no more than 8 per cohort, depending on the availability of age-matched mice in the colony). Mice were distributed randomly between the different groups. Injections and imaging were all done by N.K. and were not done blindly. Figure analysis of necrotic areas in haematoxylin and eosin (H&E) slides was done blindly. For all H&E results, different mice within each group showed similar results. Mice assigned to the experiments: NOD-SCID mice -NOD.CB17-Prkdcscid/NCrCrl (originally purchased from Charles River and maintained at the Whitehead mouse facility by self-breeding). HEL-cell-derived tumours experiment: 24 females, ages 8-11.5 weeks, mean 10.7 weeks. SEM-cell-derived tumours experiment: 26 females, ages 12-18 weeks, mean 14 weeks. HEL-cell-derived tumours long-term experiment: mice 1-22 females, mice 23-31 males, ages 6-10 weeks, mean 10 weeks. Plasmid construction. Cloning into pLentiCRISPR plasmids is described above. Mouse cDNA constructs (mouse Ftcd, mouse Hal and mouse Amdhd1) were cloned into the backbone plasmid pWPI (a contribution from the Didier Trono laboratory, Addgene plasmid number 12254) that was cut at the Pme1 site, and PCR-amplified mouse cDNA was inserted by ligation. The primers used for each gene incorporated a 5′ kozak sequence and Pme1 sites flanking the cloned gene on the 5′ and 3′ sides and are listed below. The luciferase-expression plasmid used for in vivo imaging is FUW-RLuc-T2A-PuroR, which is an FUW lentiviral backbone with the R-luciferase gene inserted downstream to a constitutive UBC promoter. The R-luciferase gene was cloned using EcoRI. The R-luciferase ORF is 936 basepairs long, missing its stop codon and is in frame with the T2A-PuroR. August 15, 2017 . Information about TARGET can be found at http://ocg.cancer.gov/programs/target. We then focused on a particular patient subset: the TARGET Substudy Acute Lymphoblastic Leukaemia (ALL) Expansion Phase 2 (phs000218.v18.p7), and further centred our analysis on patients treated with the COG AALL0232 high-risk ALL protocol (ClinicalTrials.gov Identifier NCT00075725). For patients with multiple represented tumour samples, only the first sample was used for downstream analyses. Overall survival was plotted for the upper and lower quartile of HAL, FTCD, AMDHD1 and SLC19A1 expression. Survival curves were compared by the log-rank test and P values indicated.
Kaplan-Meier curves were plotted using Prism version 7.0b. End points for patients include death and dropout of patients for reasons other than death, in which cases survival data are integrated in the curve up to the last day of follow-up. The P value was calculated using a log-rank Mantel-Cox test.
We have complied with all relevant ethical regulations while conducting this patient-derived data collection. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Data availability. The authors declare that all data generated or analysed during this study are included in this published version and its Supplementary Information Files. Source Data are provided with the online version of the paper. All other datasets generated and/or analysed in the current study are available from the corresponding author on reasonable request. Fig. 1 | Loss of FTCD decreases the sensitivity of cancer cells to methotrexate. a, Relative daily cell counts of the mixed culture of 42 genomically barcoded haematopoietic cancer cell lines. We focused our efforts on haematopoietic cell lines because methotrexate is most commonly used to treat haematopoietic malignancies 9 . Cells were cocultured and treated with three concentrations of methotrexate (0.1, 0.5, or 5 μM). Cell counts are presented relative to the vehicle-treated co-culture. n = 3, biological replicates. Error bars indicate s.d. b, Sequencing results of the competitive co-culture experiment. Heat map of relative barcode abundance for each indicated cell line after treatment with 5 μM methotrexate or vehicle after 2, 4, or 6 days compared to those in the initial cultures. c, Validation of the results of the competitive co-culture experiment as shown by individual dose-response curves of seven relatively sensitive cell lines (MOLM13, EOL-1, SUPM2, DEL, HEL, NALM6 and SUDHL1), and six relatively resistant cell lines (HL-60, Ramos, HBL-1, Raji, SUDHL8 and Jeko-1). n = 2, biological replicates. Each biological replicate included technical triplicate. Error bars indicate s.d. d, Top 40 genes that scored in the genome-wide CRISPR-Cas9based positive selection screen. These genes had the largest differential CRISPR scores between vehicle-and methotrexate-treated samples. The heat map represents the CRISPR score of two biological replicates of each screen (vehicle-and methotrexate-treated). e, Abundance of each of the individual sgRNAs targeting FTCD in the screen. Read counts for each sgRNA is presented for each of the screen biological replicates of the vehicle-treated and methotrexate-treated samples. f, Fold change in the EC 90 values of methotrexate and doxorubicin in HEL cells stably expressing shRNA targeting either SLC19A1 or FTCD compared to the average of three non-targeting shRNAs (shGFP, shRFP and shLacZ). n = 2, biological replicates. Each biological replicate included technical triplicate. Error bars indicate s.e.m. g, Expression levels of SLC19A1 (left) and FTCD (right) in HEL cells stably expressing non-targeting shRNAs (shLacZ and shGFP) or targeting shRNAs (shSLC19A1 and shFTCD). Expression levels were measured by qPCR and normalized to the average of two control genes, UBC and HPRT1. n = 3, technical replicates. Error bars indicate s.e.m. h, Validation of genetic depletion of FTCD by the CRISPR-Cas9 system in HEL, Ramos and LAMA84 cell lines. Expression of FTCD was measured by qPCR and normalized to the average of two control genes, UBC and HPRT1. n = 3 (except for HEL cells expressing sgFTCD_2 + mFTCD, then n = 2 owing to loss of RNA from one sample), biological replicates. Error bars indicate s.d.
Extended Data

Letter reSeArCH
Extended Data Fig. 3 | FTCD depletion enables cancer cells to maintain THF pools and nucleotide synthesis even when treated with methotrexate (part 2). a, b, Pool sizes of glycine (a) and serine (b) are not significantly different between FTCD-depleted and control cells. Glycine and serine levels were measured in vehicle-or methotrexate-treated HEL and Ramos cells. P values were calculated by one-way ANOVA. n = 3, biological replicates. Error bars indicate s.e.m. c, d, Greater cellular pool of 5,10-methenyl THF in methotrexate-treated cells after FTCD depletion.
[U-13 C]serine labelling of 5,10-methenyl THF showed higher abundance of unlabelled 5,10-methenyl THF in FTCD-depleted cells, compared to control cells. This suggests higher availability of 5,10-methenyl THF in these cells at the time of labelling onset, which agrees with the higher levels of both THF and 5,10-methenyl THF in the methotrexate-treated FTCD-depleted cells compared to the methotrexate-treated control cells. c, 5,10-Methenyl THF levels were measured by LC-MS in vehicle-and methotrexate-treated HEL and Ramos cells. 5,10-Methenyl THF levels were normalized to aminopterin as an internal standard. P values were calculated by one-way ANOVA. n = 3 biological replicates. Error bars indicate s.e.m. d, HEL cells were treated with 5 μM methotrexate for 48 h, and Ramos cells were treated with 20 μM methotrexate for 72 h to decrease THF levels and nucleotide synthesis in wild-type cells. The medium was then replaced with [U-13 C]serine-containing medium, and cells were incubated in [U-13 C]serine plus methotrexate for an additional 24 h followed by cell collection and LC-MS analysis. The higher abundance of unlabelled 5,10-methenyl THF suggests higher availability of reduced folate at the time of labelling onset. 5,10-Methenyl THF levels were normalized to aminopterine as an internal standard. P values were calculated for the unlabelled fraction by one-way ANOVA. n = 3, biological replicates. Error bars indicate s.e.m.
Extended Data Fig. 8 | In vivo histidine supplementation increases flux through the histidine degradation pathway and sensitizes tumours to methotrexate (part 3). THF levels decreased after methotrexate treatment and decreased even further when methotrexate was combined with histidine supplementation. Methotrexate levels were not different in tumours from mice treated with methotrexate alone or in combination with histidine supplementation. Nucleotide abundance was significantly lower in tumours from mice treated with methotrexate and histidine supplementation compared to tumours from vehicletreated mice. P values were calculated using non-parametric one-way ANOVA for all comparisons (Kruskal-Wallis test, Dunn's post hoc test), except for methotrexate, for which P values were calculated by a two tailed t-test. Vehicle (n = 6), histidine (n = 6), methotrexate (n = 6), methotrexate + histidine (n = 7). Centre bars indicate mean, error bars indicate s.e.m.
Extended Data Fig. 10 | In vivo histidine supplementation sensitizes tumours to methotrexate without enhancement of treatment toxicity (part 1). a, We evaluated whether methotrexate treatment combined with histidine supplementation might be more toxic than methotrexate alone by setting up a longer treatment regime of 15 days with a recovery period of two weeks. During the experiment we monitored weight loss and observed no difference between mice treated with methotrexate alone and those treated with methotrexate and histidine. NOD-SCID mice were injected with HEL cells subcutaneously on day 1, followed by weight measurement every other day, in vivo imaging of HEL-cellderived tumours (on days 7, 15, 20 and 28), treatment on days 12 to 23 (vehicle, histidine and methotrexate injections every other day), and final termination of the experiment after 40 days, unless an early euthanization was required in accordance with the guidelines for humane experimental end-point of the Committee on Animal Care at MIT. The experiment included four experimental groups: vehicle-treated (saline) (n = 7), histidine supplementation (n = 8), methotrexate-treated (n = 8), and histidine supplementation combined with methotrexate treatment (n = 8). Serum was collected at day 0 and day 23 for metabolite profiling and liver diagnostics. The dose of methotrexate used was 25 mg kg −1 based on the weight measured at day 0. The dose of histidine was 18 mg per injection in 400 μl saline. b, A significant reduction in tumour size over time was found in mice treated with the combination of methotrexate and histidine supplementation. Tumours were imaged in vivo by luciferase expression at the indicated days. Fold changes in tumour sizes over measurements performed on day 7 are presented. P values were calculated by nonparametric one-way ANOVA. Group size changed over time owing to mouse euthanization for humane reasons. On day 15: vehicle-treated (n = 5), histidine supplementation (n = 7), methotrexate-treated (n = 7)
and histidine supplementation combined with methotrexate treatment (n = 8). On day 20: vehicle-treated (n = 6), histidine supplementation (n = 6), methotrexate-treated (n = 7) and histidine supplementation combined with methotrexate treatment (n = 8). On day 28: vehicle-treated (n = 6), histidine supplementation (n = 5), methotrexate-treated (n = 7) and histidine supplementation combined with methotrexate treatment (n = 8). c, In vivo imaging of luciferase-expressing HEL-cell-derived tumours at days 7 (top) and 28 (bottom) . Mice are labelled by number, with the colour of the label representing their experimental group. All mice assigned to the experiment are shown, group size is the same as in a. d, e, There was no increase in the abundance of serum markers indicative of kidney damage in mice treated with methotrexate + histidine supplementation compared to mice treated with methotrexate. Markers of kidney toxicity (urea and creatinine) were measured by LC-MS in serum samples of the tested mice. The relative abundance of urea and creatinine was normalized to isotopically labelled valine and tryptophan as an internal standard. P values were calculated using non-parametric one-way ANOVA. Group size: vehicle-treated (n = 7), histidine supplementation (n = 7), methotrexate-treated (n = 8), and histidine supplementation combined with methotrexate treatment (n = 6). f, g, Some increase in livertoxicity markers in mice treated with the combined therapy compared to mice treated with methotrexate alone. Markers of liver toxicity (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) were measured by an external serum diagnostics laboratory (IDEXX) in serum samples of the tested mice. Measurement units are indicated. P values were calculated using non-parametric one-way ANOVA. Group size: vehicletreated (n = 6), histidine supplementation (n = 6), methotrexate-treated (n = 6), and histidine supplementation combined with methotrexate treatment (n = 5). Centre bars indicate mean, error bars indicate s.e.m.
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